Blair William & CO Athersys, Inc Transaction History

Blair William & CO

  • $33.4 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
SELL
$0.18 - $0.86 $2,070 - $9,890
-11,500 Reduced 23.33%
37,800 $10,000
Q4 2021

Feb 14, 2022
SELL
$0.85 - $1.4 $4,675 - $7,699
-5,500 Reduced 10.04%
49,300 $44,000
Q3 2021

Nov 12, 2021
SELL
$1.33 - $1.77 $26,600 - $35,400
-20,000 Reduced 26.74%
54,800 $73,000
Q1 2021

May 13, 2021
BUY
$1.61 - $2.77 $26,565 - $45,705
16,500 Added 28.3%
74,800 $135,000
Q4 2020

Feb 09, 2021
BUY
$1.55 - $2.24 $7,362 - $10,640
4,750 Added 8.87%
58,300 $102,000
Q3 2020

Nov 06, 2020
BUY
$1.91 - $3.08 $11,460 - $18,480
6,000 Added 12.62%
53,550 $104,000
Q2 2020

Aug 12, 2020
SELL
$1.97 - $3.98 $3,486 - $7,044
-1,770 Reduced 3.59%
47,550 $131,000
Q1 2020

May 11, 2020
BUY
$1.17 - $3.0 $9,441 - $24,210
8,070 Added 19.56%
49,320 $148,000
Q4 2019

Feb 13, 2020
SELL
$1.16 - $1.42 $1,566 - $1,917
-1,350 Reduced 3.17%
41,250 $51,000
Q3 2019

Nov 12, 2019
SELL
$1.21 - $1.65 $29,824 - $40,669
-24,648 Reduced 36.65%
42,600 $57,000
Q2 2019

Aug 13, 2019
SELL
$1.39 - $2.03 $1,806 - $2,638
-1,300 Reduced 1.9%
67,248 $113,000
Q1 2019

May 14, 2019
SELL
$1.39 - $1.71 $3,274 - $4,028
-2,356 Reduced 3.32%
68,548 $103,000
Q4 2018

Feb 14, 2019
SELL
$1.41 - $2.16 $38,070 - $58,320
-27,000 Reduced 27.58%
70,904 $102,000
Q2 2018

Aug 13, 2018
BUY
$1.76 - $2.79 $4,400 - $6,975
2,500 Added 2.62%
97,904 $193,000
Q1 2018

May 15, 2018
SELL
$1.34 - $2.03 $119,775 - $181,451
-89,385 Reduced 48.37%
95,404 $175,000
Q4 2017

Feb 14, 2018
SELL
$1.65 - $2.45 $19,255 - $28,591
-11,670 Reduced 5.94%
184,789 $334,000
Q3 2017

Nov 13, 2017
BUY
$1.5 - $2.55 $294,688 - $500,970
196,459
196,459 $405,000

About ATHERSYS, INC

ATHX Quotes by TradingView
  • Ticker ATHX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 305,110,016
  • Market Cap $3.05M
  • Description
  • Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product i...
More about ATHX
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email